Biomarker-Driven Lung Cancer

Julie Renee Brahmer, MD, MSc, discusses the issues with using tyrosine kinase inhibitors and immunotherapy in patients with locally advanced non–small cell lung cancer.

An application for FDA approval has been submitted for poziotinib as a potential treatment for patients with non–small cell lung cancer harboring HER2 exon 20 insertion mutations.

Concomitant mutations, and high PD-L1 expression may be associated with an unfavorable clinical response to second-generation tyrosine kinase inhibitors in patients with ALK-rearrange non–small cell lung cancer.

Martin Dietrich, MD, PhD, discusses the National Comprehensive Cancer Network guidelines for using MET inhibitors in patients with non–small cell lung cancer and their impact on sequencing therapies.

During a live virtual event, Ravi Salgia, MD, PhD, discussed how to decide whether to use a MET inhibitor in the first line and whether to switch to a MET inhibitor from other treatments.

During a live virtual event, Ravi Salgia, MD, PhD, discussed issues with molecular testing and biopsies including delays and affordability, plus identifying and responding to rare mutations detected by molecular testing.

Results from the phase 1b CodeBreak 101 study were favorable for the combination of sotorasib and trametinib in patients with colorectal cancer and non–small cell lung cancer.

Updated findings from the phase 1/2 TRIDENT-1 trial evaluating repotrectinib showed efficacy in patients with neurotrophic tyrosine receptor kinase fusion-positive advanced solid tumors in expanded cohorts.

Giuseppe Giaccone, MD, PhD, discusses alterations in the MET gene that can be oncogenic drivers in patients with non–small cell lung cancer.

Mark A. Socinski, MD, discusses the patient population of the trials targeting MET exon 14 skipping mutations in non–small cell lung cancer.

Martin Dietrich, MD, PhD, discusses the role MET alterations play as oncogenic drivers of non–small cell lung cancer.

During a live virtual event, Martin Dietrich, MD, PhD, discusses how to address switching treatments in response to detection of a MET gene biomarker.

During a live virtual event, Martin Dietrich, MD, PhD, discusses management of toxicities and adverse events of MET inhibitors in non–small cell lung cancer.

At a live virtual event, Martin Dietrich, MD, PhD, discusses treatment options for a patient with non–small cell lung cancer when molecular testing shows a MET exon 14 skipping mutation.

Giuseppe Giaccone, MD, PhD, discusses the results of the VISION trial of tepotinib in patients with non–small cell lung cancer.

At a live virtual event, Martin Dietrich, MD, PhD, discusses how to approach biopsies and molecular testing in coordination with pathologists and testing services for patients with non–small cell lung cancer.

Bemcentinib is currently being studied in combination with pembrolizumab and has demonstrated a good safety profile.

The assay is meant to determine patient eligibility for atezolizumab, which was granted FDA approval in PD-L1-positive lung cancer on October, 15. The assay was used in the IMpower010 study.

Atezolizumab is now approved for the adjuvant treatment of NCSLC expressing PD-L1≥1%. The approval is based on the IMpower010 study.

The breakthrough therapy designation marks the agents seventh regulatory designation.

Genomic and biomarker testing is increasing at OneOncology community cancer centers across a number of tumor types.

According to early clinical trial results, taletrectinib can induce responses in patients with ROS1-positive non–small cell lung cancer.

In patients with KRAS-mutant non–small cell lung cancer, treatment with rigosertib in combination with nivolumab showed promising signals of efficacy and safety.

Sotorasib leads to intracranial responses in patients with KRAS G12C-mutated non–small cell lung cancer, according to an update from CodeBreaK 100.

Treatment with amivantamab-vmjw in the phase 1 CHRYSALIS study has released anti-tumor activity in patients with non-small cell lung cancer harboring MET exon 14 skipping mutations treated with the agent.